FindTrial
Sign In

Efficacy and safety of hemodilutional autologous blood transfusion for intermediate- to advanced- liver resection : An observational study

Efficacy and safety of hemodilutional autologous blood transfusion for intermediate- to advanced- liver resection

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1050220063
Enrollment
50
Registered
2022-07-14
Start date
2022-07-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All disease which would be required for hepatectomy hepatectomy, hemodilutionalautologous blood transfusion (HAT)

Interventions

None listed

Sponsors

Uchida Yoichiro
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. More than 18 years 2. All disease which would be required for hepatectomy 3. intermediate-to-difficult hepatectomy 4. HAT cases

Exclusion criteria

Exclusion criteria: 1. Hepatectomy with concomitant some surgery (e.g., gastrectomy or pancreaticoduodenecrtomy) 2. Donor hepatectomy

Design outcomes

Primary

MeasureTime frame
Intraoperative allogeneic blood transfusion—

Secondary

MeasureTime frame
Intraoperative setting: bleedings(before and after HAT), amont of loss of Hb, coagulation test Postoperative setting: Complications according to the Clavien-Dindo classification, allogeneic blood transfusion (amount or rate), posthepatectomy liver failure (PHLF)—

Contacts

Public ContactTomoaki Yoh

Kyoto University Hospital

tomyoh@kuhp.kyoto-u.ac.jp+81-75-751-4323

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026